SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study

SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study

BackgroundLong-term safety and efficacy of BBIBP-CorV vaccine especially in individuals with chronic diseases, like cancer, is under investigation. In the present prospective study, we aimed to evaluate severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody response with BBIBP-CorV va...

Full description

Bibliographic Details
Main Authors: Fahimeh Safarnezhad Tameshkel, Shabnam Abedin Dargoush, Bahareh Amirkalali, Saeedeh Javadi, Ali Ghiaseddin, Yousef Alimohamadi, Ali Basi, Mahin Jamshidi Makiani, Farhad Zamani, Mohammad Hadi Karbalaie Niya
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Medicine
Subjects:
Sinopharm (BBIBP-CorV)
cancer
COVID-19 vaccine
anti-sRBD antibody response
seroconversion
anti-N IgG
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1095194/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1095194/full

Similar Items